Monitor for IND submission timing and any additional preclinical data releases. The stock has a history of negative post-announcement drift despite positive news, suggesting caution on near-term positioning.
Price Chart
Executive Summary
MIRA Pharmaceuticals announced positive preclinical results for oral MIRA-55 in a 21-day chronic inflammatory pain model, showing significant pain relief comparable to celecoxib without tolerance. The data supports advancement toward an IND submission planned for Q1 2027, but the stock has historically reacted negatively to prior bullish reports on this ticker.
Key Facts
- MIRA-55 demonstrated significant reduction in mechanical and thermal pain hypersensitivity (p < 0.001 vs vehicle) in a 21-day CFA model
- Pain relief was comparable in magnitude to celecoxib (Celebrex) at higher doses
- No evidence of tolerance observed over three weeks of daily dosing
- No adverse clinical signs or deaths reported; normal body-weight gain maintained
- IND submission planned for Q1 2027, subject to completion of remaining preclinical and regulatory activities
- DEA has determined MIRA-55 is not a controlled substance
Financial Impact
No financial data provided in the release; MIRA is a clinical-stage company with no approved products or revenue
Risk Factors
- MIRA-55 remains in preclinical development; safety and efficacy in humans not established
- Historical pattern of negative stock reaction to positive company announcements on this ticker
- IND submission in Q1 2027 is subject to completion of remaining activities and may be delayed
- Clinical-stage biotech with no revenue and high cash burn risk
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386256 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5597 (−11.02%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5597 (−11.00%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5597 (−26.29%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5597 (−26.29%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5597 (−34.92%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5597 (−17.47%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5597 (−39.46%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5597 (−41.39%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5597 (−42.78%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5597 (−42.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers